STAT+: 今日読むべきバイオテクノロジーのニュース
原題: STAT+: The biotech news you need to read today
分析結果
- カテゴリ
- 医療
- 重要度
- 57
- トレンドスコア
- 18
- 要約
- 本記事では、最新のバイオテクノロジー関連のニュースを紹介しています。業界の動向や新しい研究成果、企業の発表など、バイオテクノロジー分野で注目すべき情報がまとめられています。特に、医薬品の開発や革新的な技術に関する重要なニュースが取り上げられ、業界関係者や研究者にとって有益な内容となっています。
- キーワード
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Capricor Therapeutics is mounting a legal fight against a partner over its promising Duchenne therapy, there’s new evidence that scientific creativity calcifies with age, and STAT’s Alex Hogan and Lizzy Lawrence share firsthand accounts from FDA officials who decided the agency was no longer a place they could stay. Capricor sues partner over Duchenne therapy launch Capricor Therapeutics is suing its Japanese partner Nippon Shinyaku and subsidiary NS Pharma, arguing the companies botched launch preparations for deramiocel, the biotech’s closely watched Duchenne muscular dystrophy cell therapy. Capricor says the companies also created a pricing structure that could make the treatment financially inaccessible for many patients. Continue to STAT+ to read the full story…